Clinical Trial Update: Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of dasatinib plus ixabepilone in second- or third-line metastatic breast cancer has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)
• Sprycel (dasatinib)

Snippet

Sponsor: Accelerated Community Oncology Research Network | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-29